Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.78T
24h Vol:
$10.16B
Dominance:
MSFT:4.81%
Stocklytics Platform
Asset logo  CAPR
Capricor Therapeutics
CAPR
70 / 100
$6.29arrow_drop_down0.15%-$0.01

Performance History

Stocklytics logo
Key Stats
Open$6.31
Prev. Close$6.30
EPS-0.83
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap199458112.00
PE Ratio-
LOWHIGH
Day Range6.03
6.34
52 Week Range2.68
8.22
Ratios
P/B Ratio8.71
Revenue$25.17M
Operating M. %-209.22%
Earnings$0.00
Earnings Growth %23.20%
EBITDA Margin %-99.50%
ROE %-129.63%
EPS-0.83

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$803.16
24H (%)arrow_drop_up2.55%
24H ($)$19.98
MARKET CAP$744.33B
PRICE$523.54
24H (%)arrow_drop_up1.22%
24H ($)$6.32
MARKET CAP$476.05B
PRICE$151.24
24H (%)arrow_drop_down0.01%
24H ($)-$0.03
MARKET CAP$364.05B
PRICE$130.75
24H (%)arrow_drop_down0.17%
24H ($)-$0.23
MARKET CAP$332.27B

About Capricor Therapeutics (CAPR)

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Linda Marbán Ph.D.
Headquarters
San Diego
Employees
74
Exchange
NASDAQ
add Capricor Therapeutics  to watchlist

Keep an eye on Capricor Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Capricor Therapeutics 's (CAPR) price per share?

The current price per share for Capricor Therapeutics (CAPR) is $6.29. The stock has seen a price change of -$0.01 recently, indicating a -0.16% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Capricor Therapeutics (CAPR)?

For Capricor Therapeutics (CAPR), the 52-week high is $8.22, which is 30.68% from the current price. The 52-week low is $2.68, the current price is 134.7% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Capricor Therapeutics (CAPR) a growth stock?

Capricor Therapeutics (CAPR) has shown an average price growth of 0.41% over the past three years. It has received a score of 72 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Capricor Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Capricor Therapeutics (CAPR) stock price performance year to date (YTD)?

As of the latest data, Capricor Therapeutics (CAPR) has a year-to-date price change of 22.85%. Over the past month, the stock has experienced a price change of 27.33%. Over the last three months, the change has been 63.8%. Over the past six months, the figure is 111.78%. Looking at a longer horizon, the five-year price change stands at 98.92%.

help
Is Capricor Therapeutics (CAPR) a profitable company?

Capricor Therapeutics (CAPR) has a net income of -$22.29M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -209.22% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $25.18M, although specific revenue growth data is currently not available. The gross profit is $24.11M. Operating income is noted at -$24.08M. Furthermore, the EBITDA is -$25.05M.

help
What is the market capitalization of Capricor Therapeutics (CAPR)?

Capricor Therapeutics (CAPR) has a market capitalization of $199.46M. The average daily trading volume is 364.04K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level